Compare
Gilead Sciences, Inc. vs Amgen Inc vs Qiagen N.V. vs Bio-Techne Corp
| Latest fiscal year | Gilead Sciences, Inc. GILD | Amgen Inc AMGN | Qiagen N.V. QGEN | Bio-Techne Corp TECH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $29.44B | $36.75B | $2.09B | $1.22B |
| Revenue growth (YoY) | +2.4% | +10.0% | +5.7% | -0.4% |
| Gross margin | 78.8% (computed) | 67.2% (computed) | 62.2% | 65.8% |
| Operating margin | 34.0% | 24.7% | 22.3% | 20.7% |
| Net margin | 28.9% | 21.0% | 20.3% | 15.0% |
| Net income | $8.51B | $7.71B | $424.88M | $181.86M |
| EPS (Diluted) | $6.78 | $14.23 | $1.94 | $1.16 |
| Operating cash flow | $10.02B | $9.96B | $654.33M | $292.07M |
| Free cash flow | $9.46B | $8.10B | $453.28M | $263.22M |
| Cash & equivalents | n/a | $9.13B | $839.00M | $264.71M |
| Total assets | $59.02B | $90.59B | $6.28B | $2.59B |
| Total liabilities | n/a | n/a | n/a | n/a |
| Shareholders' equity | $22.62B | $8.66B | $3.78B | $2.11B |
| Return on year-end equity | 37.6% | 89.1% | 11.2% | 8.6% |
| Shares outstanding | 1.24B | 538.80M | n/a | 156.10M |
Revenue, most recent five fiscal years
| Fiscal year | Gilead Sciences, Inc. | Amgen Inc | Qiagen N.V. | Bio-Techne Corp |
|---|---|---|---|---|
| Latest | $29.44B Ended 2025-12-31 | $36.75B Ended 2025-12-31 | $2.09B Ended 2025-12-31 | $1.22B Ended 2026-06-30 |
| 1 year earlier | $28.75B Ended 2024-12-31 | $33.42B Ended 2024-12-31 | $1.98B Ended 2024-12-31 | $1.22B Ended 2025-06-30 |
| 2 years earlier | $27.12B Ended 2023-12-31 | $28.19B Ended 2023-12-31 | $1.97B Ended 2023-12-31 | $1.16B Ended 2024-06-30 |
| 3 years earlier | $27.28B Ended 2022-12-31 | $26.32B Ended 2022-12-31 | $2.14B Ended 2022-12-31 | $1.14B Ended 2023-06-30 |
| 4 years earlier | $27.30B Ended 2021-12-31 | $25.98B Ended 2021-12-31 | $2.25B Ended 2021-12-31 | $1.11B Ended 2022-06-30 |